Literature DB >> 11717593

Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure.

G M Felker, C M O'connor.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11717593     DOI: 10.1067/mhj.2001.119611

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  2 in total

1.  Chronic inotropic therapy in end-stage heart failure.

Authors:  Paul J Hauptman; Peter Mikolajczak; Anil George; Clinton J Mohr; Robert Hoover; Jason Swindle; Mark A Schnitzler
Journal:  Am Heart J       Date:  2006-12       Impact factor: 4.749

2.  Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.

Authors:  Paul J Hauptman; Mark A Schnitzler; Jason Swindle; Thomas E Burroughs
Journal:  JAMA       Date:  2006-10-18       Impact factor: 56.272

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.